Not exact matches
A drug approved by the Food and Drug Administration (FDA)
for melanoma in combination with a common cholesterol - lowering drug may show
promise in controlling
cancer growth in
patients with non-small cell
lung cancer (NSCLC), according to new research from the Icahn School of Medicine at Mount Sinai.
Phase I / II clinical trial results reported at the American Society
for Clinical Oncology (ASCO) Annual Meeting 2015 show
promising results
for investigational drug brigatinib against ALK + non-small cell
lung cancer (NSCLC), with 58 of 78 ALK +
patients responding to treatment, including 50 of 70
patients who had progressed after previous treatment with crizotinib, the first licensed ALK inhibitor.
Principal Investigator John Morris, MD, clinical co-leader of the Molecular Therapeutics and Diagnosis Program
for the CCC, co-leader of the UC
Cancer Institute's Comprehensive
Lung Cancer Program, professor in the division of hematology oncology at the UC College of Medicine and UC Health medical oncologist, says a number of antitumor vaccines have shown
promise for causing immune responses against tumor antigens to improve
patient outcomes.
This shows
promise for breast
cancer patients as diagnosing and treating the breast
cancer at early stages means there is a greater chance of preventing
cancer cells spreading to other tissues, such as the
lungs, brain and bone.
We are excited to evaluate our technology in combination with pembrolizumab as a potential treatment
for lung cancer, and about the
promise it may hold
for patients,» said Turnstone CEO Sammy Farah, PhD.
If clinical trials of anti-PD-1 continue to show
promising results,
cancer patients may soon have access to another powerful immunotherapy
for the treatment of numerous
cancers, including melanoma, non-small cell
lung cancer, and other solid tumors.